Table 5.
Univariate and multivariable Cox proportional hazards model analyses of PFS and OS in gastric adenocarcinoma group.
| Variables | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR (95%CI) | p | HR (95%CI) | p | HR (95%CI) | p | HR (95%CI) | p | |
| High vs. Low IL-6 | 2.879 (1.450-5.716) | 0.003* | 2.371 (1.086-5.179) | 0.014* | 2.474 (0.953-6.419) | 0.063 | 1.541 (0.548-4.333) | 0.412 |
| Male vs. Female | 0.769 (0.399-1.482) | 0.432 | 1.045 (0.421-2.593) | 0.924 | ||||
| Age ≥ 65 vs. < 65 | 1.149 (0.606-2.180) | 0.670 | 1.230 (0.508-2.976) | 0.646 | ||||
| ECOG PS 3 vs. ≤ 2 | 0.725 (0.280-1.878) | 0.507 | 1.506 (0.495-4.583) | 0.471 | ||||
| TNM IV vs. III | 2.285 (1.084-4.819) | 0.030 | 1.010 (0.431-2.363) | 0.988 | 3.514 (1.034-11.940) | 0.044* | 1.858 (0.470-7.351) | 0.377 |
| Surgery vs. no | 0.333 (0.156-0.714) | 0.005 | 0.175 (0.072-0.428) | 0.000* | 0.335 (0.111-1.009) | 0.052 | ||
| IrAEs vs. non-irAE | 0.901 (0.473-1.717) | 0.752 | 0.405 (0.167-0.982) | 0.045* | 0.598 (0.202-1.769) | 0.353 | ||
| ICIs & chemotherapy | Reference | Reference | Reference | Reference | ||||
| ICIs & targeted | 3.381 (1.522-7.509) | 0.003* | 1.366 (0.365-5.117) | 0.552 | 5.517 (2.207-13.787) | 0.000* | 0.943 (0.132-6.735) | 0.953 |
| Triple therapy | 2.214 (1.031-4.756) | 0.042* | 2.230 (0.869-5.723) | 0.092 | 0.855 (0.230-3.178) | 0.815 | 0.374 (0.071-1.981) | 0.247 |
| Treatment line ≥ 3 | 5.159 (2.522-10.553) | 0.000* | 11.039 (4.150-29.367) | 0.011* | 7.024 (2.955-16.696) | 0.000* | 5.686 (0.887-36.428) | 0.067 |
PFS, progression free survival; OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group performance status; irAEs, immune-related adverse events; ICIs, Immune checkpoint inhibitors; Triple therapy, immunotherapy combination chemotherapy with targeted therapy; HR, hazard ratio; CI, confidence interval. *p < 0.05.